wr 1065 has been researched along with Brain Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berthold, F; Fulda, S; Oster, W | 1 |
| Berens, ME; Dougherty, DV; Doz, F; Rosenblum, ML; Spencer, DR | 1 |
2 other study(ies) available for wr 1065 and Brain Neoplasms
| Article | Year |
|---|---|
Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Topics: Amifostine; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Cell Division; Cell Line; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Humans; Mercaptoethylamines; Neuroblastoma; Radiation-Protective Agents; Tumor Cells, Cultured | 1997 |
Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds.
Topics: Bone Marrow; Bone Marrow Cells; Brain Neoplasms; Carboplatin; Cell Line; Cells, Cultured; Colony-Forming Units Assay; Drug Interactions; Drug Screening Assays, Antitumor; Glioma; Humans; Mercaptoethylamines; Tumor Cells, Cultured | 1991 |